Pertuzumab (Anti-Human HER2, Humanized Antibody)
目录号 : GC34210
帕妥珠单抗（抗人 HER2，人源化抗体）是指定为 HER 二聚化抑制剂的新型药物中的第一个，是一种人源化 IgG1 单克隆抗体 (mAb)，可空间结合 erbB2 受体的结构域 II。
Cas No.:380610-27-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Pertuzumab (Anti-Human HER2, Humanized Antibody), the first of a new class of agents designated as HER dimerisation inhibitors, is a humanised IgG1 monoclonal antibody (mAb) that sterically binds domain II of the erbB2 receptor [1].
Pertuzumab may mostly act to inhibit the classical signaling pathways stimulated by active HER2, including receptor dimerization, receptor phosphorylation and the activation of signaling proteins downstream from HER receptors, including Erk and Akt [2].
Pertuzumab was approved by the FDA in 2012 to be used in combination with trastuzumab and docetaxel for treating metastatic breast cancer patients [2]. In humans, pooled analysis from one phase IA and two phase II studies in advanced disease evaluated pertuzumab pharmacokinetic parameters demonstrated minor interpatient variability in clearance and volume distribution when pertuzumab was administered with a fixed dose or based on weight (mg/kg). This supports the use of fixed dosing of pertuzumab, with an initial loading dose (840 mg) followed by a fixed dose of 420 mg every 3 weeks [3].
References:
[1]. K El-Sahwi, S Bellone, E Cocco, et al. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer, 102 (2010), pp. 134-143
[2]. Nami B, Maadi H, Wang Z. Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer. Cancers (Basel) 2018;10
[3]. Capelan, M. et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann. Oncol. 24, 273-282 (2013).
帕妥珠单抗（抗人 HER2，人源化抗体）是指定为 HER 二聚化抑制剂的新型药物中的第一种，是一种人源化 IgG1 单克隆抗体 (mAb)，可空间结合 erbB2 受体的结构域 II [ 1].
帕妥珠单抗可能主要抑制由活性 HER2 刺激的经典信号通路，包括受体二聚化、受体磷酸化和 HER 受体下游信号蛋白的激活，包括 Erk 和 Akt [2]。
帕妥珠单抗于 2012 年获得 FDA 批准与曲妥珠单抗和多西他赛联合用于治疗转移性乳腺癌患者[2]。在人类中，一项 IA 期和两项 II 期晚期疾病研究的汇总分析评估了帕妥珠单抗药代动力学参数，表明当帕妥珠单抗以固定剂量或基于体重 (mg/kg) 给药时，清除率和体积分布的患者间差异很小。这支持使用固定剂量的帕妥珠单抗，初始负荷剂量 (840 mg) 随后每 3 周固定剂量 420 mg [3]。
| Cell experiment [1]: | |
|
Cell lines |
Primary USPC cells |
|
Preparation Method |
Primary USPC cells were seeded in a 96-well plate at a density of 2000-5000 cells per well in RPMI 1640 medium with 10% foetal bovine serum. After 24 h, pertuzumab, trastuzumab, and a 1 : 1 combination of both antibodies were added at a final concentration of 20 µg ml-1. The final volume of medium per well was set at 100 µl for 48-72 h |
|
Reaction Conditions |
20 µg ml-1 for 48-72 hours |
|
Applications |
Cell proliferation was significantly inhibited in the presence of pertuzumab, trastuzumab, and the combination of the two mAbs in all USPC cell lines tested, with the percentage of inhibition varying from 4 to 59% (pertuzumab), 3 to 48% (trastuzumab), and 7 to 63% (mAbs combination) in multiple experiments. |
| Animal experiment [2]: | |
|
Animal models |
Male CD-1 mice |
|
Preparation Method |
Pertuzumab (26.7 mg/mL) and vehicle (10 mM L-histidine at pH 6.0, 240 mM sucrose, 0.02% polysorbate 20) were stored at 2-8℃. |
|
Dosage form |
3, 30, or 90 mg/kg, intravenous (IV) bolus. |
|
Applications |
The distribution phase of pertuzumab was <1 day, the terminal elimination half-life was approximately 10 days, and the volume of distribution was 27–58 mL/kg. |
|
References: [1]: K El-Sahwi, S Bellone, E Cocco, et al. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer, 102 (2010), pp. 134-143 |
|
| Cas No. | 380610-27-5 | SDF | |
| Canonical SMILES | [Pertuzumab] | ||
| 分子式 | 分子量 | 145175.18 | |
| 溶解度 | Soluble in water | 储存条件 | Store at -80°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.0069 mL | 0.0344 mL | 0.0689 mL |
| 5 mM | 0.0014 mL | 0.0069 mL | 0.0138 mL |
| 10 mM | 0.0007 mL | 0.0034 mL | 0.0069 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。